---
schema_version: "secwatch.filing_event.v1"
accession: "0001683168-24-008118"
form_type: "8-K"
ticker: "PHIO"
cik: "0001533040"
company_name: "Phio Pharmaceuticals Corp."
filed_at: "2024-11-14T23:59:59+00:00"
generated_at: "2026-05-30T00:26:41.397983+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.55
calibrated_materiality_score: 0.55
confidence: "high"
source: SEC EDGAR
---

# Phio Pharma Q3 net loss $1.5M, cash $5.4M; PH-762 shows complete response in one patient

## Summary
- Net loss narrowed to $1.5M for Q3 2024 vs $2.8M in Q3 2023; R&D expenses fell 64% to $0.6M.
- Cash at Sept 30, 2024 was $5.4M, down from $8.5M at Dec 31, 2023.
- Phase 1b of PH-762: second cohort enrolled; one complete response (100% tumor clearance) and one partial response (90%) in cutaneous squamous cell carcinoma.
- Warrant inducement exercise in July 2024 raised net proceeds of ~$2.6M.
- Third cohort screening opens Dec 10, 2024; sixth clinical site added in San Diego.

## SEC filing metadata
- accession: 0001683168-24-008118
- form_type: 8-K
- ticker: PHIO
- cik: 0001533040
- company_name: Phio Pharmaceuticals Corp.
- filed_at: 2024-11-14T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.55
- calibrated_materiality_score: 0.55
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1533040/000168316824008118/0001683168-24-008118-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1533040/000168316824008118/phio_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001683168-24-008118
- JSON: https://secwatch.observer/filing/0001683168-24-008118.json
- Plain text: https://secwatch.observer/filing/0001683168-24-008118.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.